Combined somatic mutation and copy number analysis in the survival of familial CLL.

Combined somatic mutation and copy number analysis in the survival of familial CLL.
复制标题

DOI:
10.1111/bjh.15239
复制
发表时间:
2018-06
影响因子:
6.5
通讯作者:
Caporaso NE
Caporaso NE
中科院分区:
医学2区
文献类型:
--
作者:
Zhou W;Goldin L;Wang M;McMaster ML;Jones K;Burdett L;Chanock SJ;Yeager M;Dean M;Caporaso NE

文献摘要

参考文献

被引文献

相似文献

复发性大规模体细胞拷贝数改变(SCNAs)和体细胞点突变可以被分析,以将慢性淋巴细胞白血病(CLL)患者分为不同的预后组。为了研究SCNAs与体细胞突变之间的关系,我们对来自40个CLL高负担家庭的98名CLL患者进行了全外显子组测序和单核苷酸多态性微阵列分析。总体而言,在45名受试者(46%)中检测到29个CLL驱动基因中的69个体细胞突变,其中最常见的突变基因是TP 53(8.2%),NOTCH 1(8.2%)和ATM(5.1%)。此外,从54名受试者(57%)中检测到142个SCNA,包括染色体13 q14(28.9%),11 q(5.6%),17 p(2.1%)丢失和染色体12(4.2%)增加。我们发现,在CLL驱动基因中同时存在不利点突变和不利SCNA的患者的生存率往往较差(风险比[HR]=3.17,95%置信区间[CI]=0.97-10.35; P=0.056)(HR = 1.34,95%CI=0.66-2.71; P = 0.42)或SCNA(HR = 2.65,95%CI=0.77-9.13; P = 0.12)。TP 53突变携带者的总生存率最低(HR=4.39,95%CI=1.28-15.04; P=0.018)。我们的研究表明,结合SCNA和突变数据可能有助于预测家族性CLL的结果。
Recurrent large-scale somatic copy number alterations (SCNAs), and somatic point mutations can be analysed to stratify patients with chronic lymphocytic leukaemia (CLL) into distinct prognostic groups. To investigate the relationship between SCNAs and somatic mutations, we performed whole-exome sequencing and single nucleotide polymorphism microarray analyses on 98 CLL patients from 40 families with a high burden of CLL. Overall, 69 somatic mutations in 29 CLL driver genes were detected among 45 subjects (46%), with the most frequently mutated genes being TP53 (8.2%), NOTCH1 (8.2%) and ATM (5.1%). Additionally, 142 SCNAs from 54 subjects (57%) were detected, including losses of chromosome 13q14 (28.9%), 11q (5.6%), 17p (2.1%), and gain of chromosome 12 (4.2%). We found that patients having both an adverse point mutation in a CLL driver gene and an unfavourable SCNA tended to have poorer survival (Hazard ratio [HR]=3.17, 95% confidence interval [CI]=0.97–10.35; P=0.056) than patients having either a point mutation (HR = 1.34, 95%CI=0.66–2.71; P = 0.42) or SCNAs (HR = 2.65, 95%CI=0.77–9.13; P = 0.12). TP53 mutation carriers were associated with the poorest overall survival (HR=4.39, 95%CI=1.28–15.04; P=0.018). Our study suggests that combining SCNA and mutational data could contribute to predicting outcome in familial CLL.
DOI: 10.3109/10428190109097681
发表时间: 2001-06-01
影响因子: 2.6
作者:
Ishibe, N;Sgambati, MT;Caporso, NE
通讯作者: Caporso, NE
DOI: 10.1053/j.seminhematol.2014.05.004
发表时间: 2014-07
影响因子: 3.6
作者:
Gruber M;Wu CJ
通讯作者: Wu CJ
DOI: 10.1158/1078-0432.ccr-10-0151
发表时间: 2010-12-01
影响因子: 11.5
作者:
Mosca, Laura;Fabris, Sonia;Neri, Antonino
通讯作者: Neri, Antonino
使用下一代 DNA 测序数据进行变异发现和基因分型的框架。
DOI: 10.1038/ng.806
发表时间: 2011-05
期刊: Nature genetics
影响因子: 30.8
作者:
通讯作者: --
推动CLL的突变及其在进展和复发中的演变。
DOI: 10.1038/nature15395
发表时间: 2015-10-22
期刊: Nature
影响因子: 64.8
作者:
Landau DA;Tausch E;Taylor-Weiner AN;Stewart C;Reiter JG;Bahlo J;Kluth S;Bozic I;Lawrence M;Böttcher S;Carter SL;Cibulskis K;Mertens D;Sougnez CL;Rosenberg M;Hess JM;Edelmann J;Kless S;Kneba M;Ritgen M;Fink A;Fischer K;Gabriel S;Lander ES;Nowak MA;Döhner H;Hallek M;Neuberg D;Getz G;Stilgenbauer S;Wu CJ
通讯作者: Wu CJ